Elan blocks Royalty bid in court

US-based investment firm Royalty Pharma is unable to go ahead with its hostile $6.4bn bid for Irish drug firm Elan for now, following a New York court ruling. The court will decide on 11 June whether or not to grant a preliminary injunction against Royalty.